|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, February 14, 2017 ) Pharmaceutical and Healthcare disease pipeline guide Lennox-Gastaut Syndrome - Pipeline Review, H2 2016, provides an overview of the Lennox-Gastaut Syndrome (Central Nervous System) pipeline landscape.
Lennox-Gastaut syndrome is a severe form of epilepsy that typically becomes apparent during infancy or early childhood. The most common types of seizures associated with Lennox-Gastaut syndrome are tonic and atonic seizures. Causes of Lennox-Gastaut syndrome include cortical dysplasia, congenital infections, stroke, trauma, perinatal hypoxia, infections of the central nervous system such as encephalitis or meningitis and a rare, genetic disorder called tuberous sclerosis. Treatment includes antiepileptic drugs, dietary therapy and surgery.
For more information about this report at http://www.reportsweb.com/lennox-gastaut-syndrome-pipeline-review-h2-2016
Pharmaceutical and Healthcare latest pipeline guide Lennox-Gastaut Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Lennox-Gastaut Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Lennox-Gastaut Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Lennox-Gastaut Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Lennox-Gastaut Syndrome.
Lennox-Gastaut Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Lennox-Gastaut Syndrome (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Lennox-Gastaut Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Lennox-Gastaut Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Lennox-Gastaut Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Lennox-Gastaut Syndrome (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Lennox-Gastaut Syndrome (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Lennox-Gastaut Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001506609/sample
Table of Content
Headlines
Trends
Competitive Landscape
Prospects
Category Data
Lennox-Gastaut Syndrome Overview 6
Therapeutics Development 7
Pipeline Products for Lennox-Gastaut Syndrome - Overview 7
Pipeline Products for Lennox-Gastaut Syndrome - Comparative Analysis 8
Lennox-Gastaut Syndrome - Therapeutics under Development by Companies 9
Lennox-Gastaut Syndrome - Therapeutics under Investigation by Universities/Institutes 10
Lennox-Gastaut Syndrome - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Lennox-Gastaut Syndrome - Products under Development by Companies 14
Lennox-Gastaut Syndrome - Products under Investigation by Universities/Institutes 15
Lennox-Gastaut Syndrome - Companies Involved in Therapeutics Development 16
Eisai Co Ltd 16
GW Pharmaceuticals Plc 17
INSYS Therapeutics Inc 18
Zogenix Inc 19
Lennox-Gastaut Syndrome - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001506609/buy/2000
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
